SN · Pharma and healthcare · one day
Smith & Nephew (SN): news on Thursday 5 November 2026
News from the 24 hours to Thursday morning, 5 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage focused on Smith & Nephew lowering its 2026 guidance because of weak US orthopaedics and wound care sales, alongside the end of talks with Johnson & Johnson's orthopaedics unit. Shares were reported sliding, though the company is still reviewing options for its orthopaedics business.
What drove it
- guidance cut
- US orthopaedics weakness
- ended J&J talks
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 30 Oct | −4.7 | 1 |
| Sun 1 Nov | 0.0 | 1 |
| Tue 3 Nov | +5.0 | 2 |
| Wed 4 Nov | −1.7 | 4 |
| Thu 5 Nov | −8.3 | 19 |
3 stories · 19 headlines · strongest first
Pharma and healthcare on 5 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Smith & Nephew lowers 2026 guidance and ends talks with J&J −4.015 headlines today · 20 in all, since 9 October · Smith & Nephew reported $1.55bn in revenue for the third quarter, lowered its expectations for the whole year because its US orthopaedics business was softer, and ended discussions with J&J about a merger. | ||
| −10.0 | Lower guidance driven by declining US hip and knee demand. | |
| −10.0 | Lower annual guidance because of US orthopaedics weakness. | |
| −10.0 | Annual guidance lowered as US orthopaedics demand weakens. | |
| −10.0 | Quarterly revenue below forecasts and weaker outlook on US market. | |
| −9.2 | Share price falling on the day after the update. | |
| −9.2 | Share price falling on the day after the update. | |
| −8.3 | Lowered forecast and collapse of discussions with a large peer. | |
| −8.3 | Talks with rival's orthopaedics unit ended and revenue outlook reduced. | |
| −5.8 | Revenue grew but forecast was lowered. | |
| −5.0 | Quarter grew but annual expectations were reduced. | |
| −3.3 | Official quarterly update; context elsewhere shows weak outlook. | |
| +3.3 | Earnings per share ahead of forecasts and shares reportedly higher. | |
| 0.0 | Presentation material for the quarterly trading update, purely factual. | |
| 0.0 | Brief factual revenue figure for the quarter. | |
| 0.0 | Preview of upcoming trading report, no outcome yet. | |
| Smith & Nephew is open to a deal on orthopaedics −1.93 headlines today · The company confirmed a review of options for its orthopaedics business. | ||
| −6.7 | Lowered outlook, though company still pursuing a transaction. | |
| +1.7 | Company reportedly willing to consider a transaction for its orthopaedics division. | |
| −0.8 | Company assessing strategic alternatives for orthopaedics, outcome uncertain. | |
| Jefferies expects Smith & Nephew shares to fall −10.01 headline today · Jefferies said the reduced guidance and soft sales in wound care indicate Smith & Nephew's shares will fall. | ||
| −10.0 | Broker expects shares to drop after lowered guidance and weak wound care. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated Smith & Nephew: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.